Infections Related to Biologics: Agents Targeting B Cells

Area of Science:

• Immunology
• Pharmacology
• Rheumatology

Background:

• B cells are crucial for adaptive immunity.
• Biologic drugs targeting B cells have been used since the late 1990s.
• These therapies treat B-cell lymphoproliferative and autoimmune diseases, especially those with autoantibodies.

Purpose of the Study:

• To review the use of B-cell targeting biologic drugs.
• To discuss the association of these drugs with serious infections.
• To explore the difficulty in attributing infectious complications solely to B-cell therapies.

Main Methods:

• Review of scientific literature on B-cell targeting biologic agents.
• Analysis of reported infectious complications associated with these therapies.
• Discussion of confounding factors in attributing causality of infections.

Main Results:

• B-cell targeting agents are effective in treating various conditions.
• Serious infections, including opportunistic ones, are a known risk.
• Distinguishing drug-related infections from those caused by other immunosuppressants or the underlying disease is complex.

Conclusions:

• While B-cell targeting biologics offer therapeutic benefits, they carry risks of severe infections.
• Careful patient monitoring and consideration of all contributing factors are essential.
• Further research may be needed to clarify the precise contribution of these agents to infectious complications.